Quality of Care: The Challenges, The Solutions

Abstract

Psoriatic arthritis (PsA) and hidradenitis suppurativa (HS) are both immune-mediated diseases with common cellular and cytokine pathways involved in their pathogenesis.1 Both are characterised by chronic and systemic inflammation and both involve elevated levels of the cytokines tumour necrosis factor-α (TNF-α), interleukin-17, and interleukin-23.1-5 PsA and HS are associated with substantial unmet needs and are sub-optimally managed. This educational session discussed ways to improve the quality of care and patient outcomes in PsA and HS. Dr Kim Papp opened the symposium with an overview of the current unmet needs in PsA and HS and the key barriers to improving the management of both diseases. Prof Hilary Thomas discussed the Quantum initiative and how it could assist dermatologists in the treatment of PsA and HS. Dr Papp and Prof Christos C. Zouboulis then discussed the challenges of achieving optimal management in PsA and HS, as well as the solutions.